149 related articles for article (PubMed ID: 24215127)
1. Intravitreal injection of ranibizumab for treatment of age-related macular degeneration: effects on serum VEGF concentration.
Gu X; Yu X; Dai H
Curr Eye Res; 2014 May; 39(5):518-21. PubMed ID: 24215127
[TBL] [Abstract][Full Text] [Related]
2. Systemic levels of vascular endothelial growth factor before and after intravitreal injection of aflibercept or ranibizumab in patients with age-related macular degeneration: a randomised, prospective trial.
Zehetner C; Kralinger MT; Modi YS; Waltl I; Ulmer H; Kirchmair R; Bechrakis NE; Kieselbach GF
Acta Ophthalmol; 2015 Mar; 93(2):e154-9. PubMed ID: 25488124
[TBL] [Abstract][Full Text] [Related]
3. Endothelial progenitor cells and plasma vascular endothelial growth factor and stromal cell-derived factor-1 during ranibizumab treatment for neovascular age-related macular degeneration.
Grierson R; Meyer-Rüsenberg B; Kunst F; Berna MJ; Richard G; Thill M
J Ocul Pharmacol Ther; 2013; 29(6):530-8. PubMed ID: 23573802
[TBL] [Abstract][Full Text] [Related]
4. Systemic counterregulatory response of placental growth factor levels to intravitreal aflibercept therapy.
Zehetner C; Bechrakis NE; Stattin M; Kirchmair R; Ulmer H; Kralinger MT; Kieselbach GF
Invest Ophthalmol Vis Sci; 2015 May; 56(5):3279-86. PubMed ID: 26024110
[TBL] [Abstract][Full Text] [Related]
5. Serum and plasma vascular endothelial growth factor concentrations before and after intravitreal injection of aflibercept or ranibizumab for age-related macular degeneration.
Wang X; Sawada T; Sawada O; Saishin Y; Liu P; Ohji M
Am J Ophthalmol; 2014 Oct; 158(4):738-744.e1. PubMed ID: 24973606
[TBL] [Abstract][Full Text] [Related]
6. Neovascular age-related macular degeneration: intraocular cytokines and growth factors and the influence of therapy with ranibizumab.
Funk M; Karl D; Georgopoulos M; Benesch T; Sacu S; Polak K; Zlabinger GJ; Schmidt-Erfurth U
Ophthalmology; 2009 Dec; 116(12):2393-9. PubMed ID: 19815292
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic rationale for dosing every 2 weeks versus 4 weeks with intravitreal ranibizumab, bevacizumab, and aflibercept (vascular endothelial growth factor Trap-eye).
Stewart MW; Rosenfeld PJ; Penha FM; Wang F; Yehoshua Z; Bueno-Lopez E; Lopez PF
Retina; 2012 Mar; 32(3):434-57. PubMed ID: 22374154
[TBL] [Abstract][Full Text] [Related]
8. SERUM LEVELS OF VASCULAR ENDOTHELIAL GROWTH FACTOR BEFORE AND AFTER INTRAVITREAL INJECTION OF RANIBIZUMAB OR CONBERCEPT FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION.
Jin E; Bai Y; Luo L; Huang L; Zhu X; Ding X; Qi H; Zhao M
Retina; 2017 May; 37(5):971-977. PubMed ID: 27617537
[TBL] [Abstract][Full Text] [Related]
9. Influence of ranibizumab on vascular endothelial growth factor plasma level and endothelial progenitor cell mobilization in age-related macular degeneration patients: safety of intravitreal treatment for vascular homeostasis.
Machalińska A; Paczkowska E; Pabin T; Safranow K; Karczewicz D; Machaliński B
J Ocul Pharmacol Ther; 2011 Oct; 27(5):471-5. PubMed ID: 21830945
[TBL] [Abstract][Full Text] [Related]
10. VEGF gene polymorphism and response to intravitreal ranibizumab in neovascular age-related macular degeneration.
Veloso CE; de Almeida LN; Recchia FM; Pelayes D; Nehemy MB
Ophthalmic Res; 2014; 51(1):1-8. PubMed ID: 24157918
[TBL] [Abstract][Full Text] [Related]
11. Vascular endothelial growth factor in patients with exudative age-related macular degeneration treated with ranibizumab.
Muether PS; Hermann MM; Viebahn U; Kirchhof B; Fauser S
Ophthalmology; 2012 Oct; 119(10):2082-6. PubMed ID: 22920670
[TBL] [Abstract][Full Text] [Related]
12. Vascular endothelial growth factor plasma levels before and after treatment of neovascular age-related macular degeneration with bevacizumab or ranibizumab.
Carneiro AM; Costa R; Falcão MS; Barthelmes D; Mendonça LS; Fonseca SL; Gonçalves R; Gonçalves C; Falcão-Reis FM; Soares R
Acta Ophthalmol; 2012 Feb; 90(1):e25-30. PubMed ID: 21958440
[TBL] [Abstract][Full Text] [Related]
13. Intravitreal ranibizumab may induce retinal arteriolar vasoconstriction in patients with neovascular age-related macular degeneration.
Papadopoulou DN; Mendrinos E; Mangioris G; Donati G; Pournaras CJ
Ophthalmology; 2009 Sep; 116(9):1755-61. PubMed ID: 19560206
[TBL] [Abstract][Full Text] [Related]
14. Comparative study of intravitreal bevacizumab (Avastin) versus ranibizumab (Lucentis) in the treatment of neovascular age-related macular degeneration.
Landa G; Amde W; Doshi V; Ali A; McGevna L; Gentile RC; Muldoon TO; Walsh JB; Rosen RB
Ophthalmologica; 2009; 223(6):370-5. PubMed ID: 19590252
[TBL] [Abstract][Full Text] [Related]
15. Anti-VEGF treatment patterns for neovascular age-related macular degeneration among medicare beneficiaries.
Lad EM; Hammill BG; Qualls LG; Wang F; Cousins SW; Curtis LH
Am J Ophthalmol; 2014 Sep; 158(3):537-43.e2. PubMed ID: 24857687
[TBL] [Abstract][Full Text] [Related]
16. Long-term alterations of systemic vascular endothelial growth factor levels in patients treated with ranibizumab for age-related macular degeneration.
Enders P; Muether PS; Hermann M; Ristau T; Fauser S
Retina; 2015 Mar; 35(3):454-8. PubMed ID: 25170863
[TBL] [Abstract][Full Text] [Related]
17. [The impact of locally administrated VEGF inhibitors on vascular homeostasis--controversies concerning safety of intravitreal therapy in AMD patients].
Machalińska A
Klin Oczna; 2012; 114(1):63-7. PubMed ID: 22783749
[TBL] [Abstract][Full Text] [Related]
18. Long-term stability of vascular endothelial growth factor suppression time under ranibizumab treatment in age-related macular degeneration.
Muether PS; Hermann MM; Dröge K; Kirchhof B; Fauser S
Am J Ophthalmol; 2013 Nov; 156(5):989-993.e2. PubMed ID: 23938122
[TBL] [Abstract][Full Text] [Related]
19. Stroke rates after introduction of vascular endothelial growth factor inhibitors for macular degeneration: a time series analysis.
Campbell RJ; Bell CM; Paterson JM; Bronskill SE; Moineddin R; Whitehead M; Gill SS
Ophthalmology; 2012 Aug; 119(8):1604-8. PubMed ID: 22717458
[TBL] [Abstract][Full Text] [Related]
20. Intravitreal ranibizumab versus thermal laser photocoagulation in the treatment of extrafoveal classic choroidal neovascularization secondary to age-related macular degeneration.
Ladas ID; Chatziralli IP; Kotsolis AI; Douvali M; Georgalas I; Theodossiadis PG; Rouvas AA
Ophthalmologica; 2012; 228(2):93-101. PubMed ID: 22571933
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
